Clinical trial registry record

A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated October 23, 2019.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02730208
Last registry update
October 23, 2019
Status
Completed
Phase
Phase 2
Sponsor
Vertex Pharmaceuticals Incorporated
Enrollment
41
Countries
Australia
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
41
Population
ALL · 12 Years
Duration
2016-09-01 to 2018-07-01
Intervention
Tezacaftor/Ivacaftor; Ivacaftor; Placebo
Comparator
Placebo
Outcomes measured
Absolute Change in Total Brody/CF-CT Score — From Baseline at Week 72; Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — Day 1 up to Wee…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Extracellular matrix ageing · 100%Title contains controlled term: fibrosis. Source terminology contains: fibrosis. Title supplies longevity context: aging. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

extracellular matrix aging
Open primary sourceExport JSON